The Board of Directors of the Foundation for the National Institutes of Health (FNIH), after an extensive search, has named Dr. Scott Campbell as its new executive director and chief executive officer.

"We are delighted Dr. Campbell will be at the helm of the foundation and, given his experience and background in biomedical, programmatic and donor development, are confident in his ability to take the organization to the next level," noted FNIH Chairman Dr. Charles A. Sanders.

FNIH supports the mission of the National Institutes of Health (NIH) through a wide range of initiatives that advance human health through public-private, collaborative partnerships. The foundation is a leader in identifying and addressing complex scientific and health issues, leveraging the diverse strengths of stakeholders in the science and research community, industry, academia, advocacy groups, non-governmental organizations, foundations and philanthropy.

"I am honored to serve as the new Executive Director of the foundation and look forward to working with the staff and colleagues of the foundation, NIH and the private sector to further the mission of NIH. In this era of scientific complexity, as research, development and health delivery costs continue to increase, efforts at making the critical scientific advances needed to improve public health in the U.S., and globally, require collaboration between the public and private sectors. I will look for new and creative ways to fulfill the mission of the foundation," said Campbell.

Dr. Scott Campbell

Prior to joining the foundation, Dr. Campbell served as the national vice president of research programs at the American Diabetes Association (ADA). Dr. Campbell joined the ADA in 2001 and in his capacity as national vice president, reported to both the ADA National Board of Directors and the ADA Research Foundation Board.

In addition to overseeing all research related programs at the ADA, Dr. Campbell was responsible for acquiring major donations for the ADA Research Foundation, and also had primary responsibility for oversight of the ADA Research Grant Review Committee, Research Policy Committee, and the Scientific and Healthcare Council. He also served as liaison for the ADA to federal research efforts at the National Institutes of Health, Veterans Administration, Centers for Disease Control, and U.S. Food and Drug Administration.

Dr. Campbell was invited to provide input to the strategic planning efforts of the NIH National Center for Research Resources and the National Institute of Diabetes, Digestive and Kidney Disease. Internationally, Dr. Campbell was the ADA Research Program liaison to the European Association for the Study of Diabetes (EASD) and the International Diabetes Federation (IDF). He continues to serve as a senior consultant to the China-America Institute of Diabetic Complications in the School of Pharmacy, Wenzhou Medical College.

Dr. Campbell represented the ADA on numerous external panels and committees. He served as a member of the board of trustees for the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), as a member of the Institute of Medicine's Clinical Research Roundtable, and is a current member of the Forum on Drug Discovery, Development and Translation for the Institute of Medicine at the National Academies. He also served until recently on the board of directors for the Health Research Alliance, as well as treasurer for this organization.

Campbell received his Ph.D. in Basic Biomedical Sciences in 1985 from the University of South Florida. Following postdoctoral training in cardiovascular physiology at the University of Ottawa in Canada, he spent 12 years in academia at the Michael Reese Hospital in Chicago, the University of Missouri, and the University of South Dakota, where his primary area of research was hypertension, heart failure, and the renin-angiotensin system. During that time, he authored 41 peer-reviewed articles, nine invited reviews, and 14 book chapters.

Campbell will serve as the third executive director of the foundation and replaces Amy Porter who resigned in February to become the Executive Director and CEO of the National Osteoporosis Foundation.